Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29897705 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL6491181 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL29897709 | 0.90 | APEX1 (0.49) | ALDH1A1LMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL6490243 | 0.90 | APEX1 (0.49) | ALDH1A1LMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL6490246 | 0.90 | APEX1 (0.49) | ALDH1A1LMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL3029547 | 0.87 | TSHR (0.56) | ALDH1A1LMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL25926241 | 0.84 | ALDH1A1 (0.41) | ALDH1A1LMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL25925529 | 0.83 | ALDH1A1 (0.41) | ALDH1A1LMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL7745394 | 0.82 | ALDH1A1 (0.53) | ALDH1A1LMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL6691847 | 0.80 | LMNA (0.44) | ALDH1A1LMNAHTTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113350301-B | New compound traditional Chinese medicine honeyed pill for treating impotence | 刘宝顺 | 2022-10-04 | — | — | CN | claimed |
| CN-113350301-A | New compound traditional Chinese medicine honeyed pill for treating impotence | 刘宝顺 | 2021-09-07 | — | — | CN | claimed |
| US-20250041309-A1 | USE OF AILDENAFIL OR SALT THEREOF IN PREPARATION OF MEDICINE FOR PREVENTING OR TREATING ISCHEMIC BRAIN DAMAGE | ZHENAO JINYINHUA PHARMACEUTICAL (CN) | 2025-02-06 | — | — | US | disclosed |
| CN-116262118-B | Application of alidenafil or salt thereof in preparation of medicines for preventing or treating ischemic brain injury | 真奥金银花药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023109513-A1 | USE OF AILDENAFIL OR SALT THEREOF IN PREPARATION OF MEDICINE FOR PREVENTING OR TREATING ISCHEMIC BRAIN DAMAGE | 真奥金银花药业有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-116262118-A | Application of alidenafil or salt thereof in preparation of medicines for preventing or treating ischemic brain injury | 真奥金银花药业有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-113350301-B | New compound traditional Chinese medicine honeyed pill for treating impotence | 刘宝顺 | 2022-10-04 | — | — | CN | disclosed |
| CN-113350301-A | New compound traditional Chinese medicine honeyed pill for treating impotence | 刘宝顺 | 2021-09-07 | — | — | CN | disclosed |
| EP-1400522-B1 | COMPOUNDS FOR TREATING IMPOTENCE | GUANGZHOU YOUCARE BIOPHARMACEATICS CO LTD (CN) | 2014-08-06 | — | — | EP | disclosed |
| US-6960592-B2 | 1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one compound for the treatment of impotence | LIU BAOSHUN | 2005-11-01 | — | — | US | disclosed |
| US-20040152709-A1 | New compound for the treatment of impotence | LIU BAOSHUN (CN) | 2004-08-05 | — | — | US | disclosed |
| EP-1400522-A1 | NEW COMPOUNDS FOR TREATING IMPOTENCE | Liu, Baoshun (CN) | 2004-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041309-A1 | USE OF AILDENAFIL OR SALT THEREOF IN PREPARATION OF MEDICINE FOR PREVENTING OR TREATING ISCHEMIC BRAIN DAMAGE | PDE5A, PDE3A, PDE2A | ALDH1A1 451/4885LMNA 753/4885HTT 3209/4885 |
| US-20040152709-A1 | New compound for the treatment of impotence | PDE3B, PDE3A, PDE5A | ALDH1A1 221/4885LMNA 2553/4885HTT 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.